Member Info for deepjoy

people look to blame others; anyone but themselves when things appear to go against them. It's not as if JW or anyone but a gun to your heads to buy a share and lets face it both here and finwit is a swamp for those influencers... There is no great conspiracy going on here nor is there any deflection from the decisions each and every one of us makes to invest... Stop navel gazing and looking for excuses this company could be the toast of the markets in a day or so, or maybe not, but the buck only stops with oneself.

No I dont like Cathal's strategy and have no real interest in the spin offs. I look at the revenue projections and Mcap now and think it is fair value, not redicuously cheap but everyone here will disagree on that point. Yes it could gap down to 16.4 but if it does it will be very cheap and I will double up then. See how it goes..

That 100k was me... not quite my target price but hey this share is fair value

let's looks at the scenario ... company receive news and have to review and prepare RNS... NOMAD must review which given the time delays mean any amendments / advice are overnight lead times.. company review and RNS is published.. not saying good or bad news just saying the delay makes sense

don't be childish ...

fleeced ... no bottle as per usual

They tend to update it a day late from 10am our time onwards

conspiracy theorists will navel gaze and read the tea leaves on what no news yet means... Truth is no ones knows a thing and it is important to remember that being US based any news would have to be compiled and thereafter screened by their NOMAD here... so it is what it is a delay ...

here's a link on FDA performance https://www.agencyiq.com/fda-new-drug-approvals-unphased-by-covid-19-so-far/

In their last performance report last year they reported that the pandemic had not affected their performance targets and that target dates were still being hit.. It's on their website

If people have held this long and hold for news they wont want to give their shares away ..or at least I hope they wont after putting themselves in a binary position play

Three... I don't agree with that but understand it. The approval is a pivotol point for the company and the share has been traded infinitum over the past through days. The RSI is only around 64 and with the risk adverse watching it has room to spike far higher before reaching over bought. just my view

Duly,,, no this is retail doing what they always do - worry and sell then buy higher later sadly

Me to Thompi :)... I may have disagreed with Meastro in the timescales but I do agree with him on the potential of this fabulous company

here it is - BUT yesterdays approvals were added at 10am this morning so don't put much store in it. I have no doubt that the company will release the news before it is available by any other means
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=reportsSearch.process

There is a reason most retail investors don't make big gains.... lack of bottle! If people have held this share over night but sell today then they deserve to miss out on big returns in the future. Retail think themselves out of great investments all the time and this allows institutional investors to win every time.. rewards come with risk but the biggest rewards come with patience and bottle GLA

It is very unlikely that we will know the outcome of the FDA decision in market hours tomorrow. Their website on approvals has not been updated so far today and last Friday wasn't until after 4pm.. so dont expect an RNS AM

You said £3 in a few weeks and I say £3 in maybe 18 months... That's it in a nutshell - TIME

There is no dispute this tech is needed it's your forecasting that is way off. The first strategic aim for the company is to target US teaching hospitals first before the rest of the US market. Likewise it takes time to get approvals in other countries which again take time and costs money. This company be worth ten times current valuations BUT is wont be overnight as unless they raise again the financing has to come from organic growth. The de-risked target of 1.50 is, in my view, correct assuming growth forecasting for the next three years.

Maestro - I've held this share over two years and I do understand the technology likewise so do the brokers and some big investors who, rightly point out that the management team have yet to be really tested on securing commercial sales and negotiation. There is no way Bracco would move that fast nor any other suitor so please stop ramping for ramping sake and stick to the numbers particularly as they are reliant on the effeciency of third parties to supply it to market in any demand scenerio.